Informações de Amarin Corporation PLC

Mais detalhes de Amarin Corporation PLC Empresa

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.



Código da empresaAMRN

Nome da EmpresaAmarin Corporation PLC

Data de listagemApr 01, 1993

CEOMr. Aaron D. Berg

Número de funcionários275

Tipo de títulosDepository Receipt

Fim do ano fiscalApr 01

EndereçoWeWork One Central Plaza Dame Street

CidadeDUBLIN

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísIreland

Código postalD02 K7K5

Telefone35316699020

Sitehttps://amarincorp.com/

Código da empresaAMRN

Data de listagemApr 01, 1993

CEOMr. Aaron D. Berg

Executivos da empresa Amarin Corporation PLC



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

--

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

--

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

--

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

--

Ms. Patrice Bonfiglio

Non-Executive Independent Director

--

Mr. Louis Sterling, III

Non-Executive Independent Director

--

Mr. Peter Fishman

Chief Financial Officer

--

Dr. Stephen B. (Steven) Ketchum, Ph.D.

President - Research and Development, Executive Vice President, Chief Scientific Officer

--

Mr. Aaron D. Berg

President, Chief Executive Officer, Director

--

Mr. Keith L. Horn

Non-Executive Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

--

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

--

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

--

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

--

Ms. Patrice Bonfiglio

Non-Executive Independent Director

--

Mr. Louis Sterling, III

Non-Executive Independent Director

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: dom, 26 de out

Investidores

Tipos de investidores

Investidores

Proporção

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

1.16%

Eversept Partners, LP

0.80%

Morgan Stanley & Co. LLC

0.71%

Outro

88.58%

Investidores

Proporção

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

1.16%

Eversept Partners, LP

0.80%

Morgan Stanley & Co. LLC

0.71%

Outro

88.58%

Tipos de investidores

Investidores

Proporção

Hedge Fund

11.40%

Investment Advisor

2.98%

Investment Advisor/Hedge Fund

1.81%

Research Firm

1.32%

Individual Investor

0.99%

Family Office

0.24%

Foundation

0.18%

Pension Fund

0.09%

Outro

81.00%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

311

3.72M

17.89%

-1.05M

2025Q2

337

3.85M

18.61%

-1.56M

2025Q1

349

5.67M

20.22%

+144.25K

2024Q4

362

81.89M

19.91%

-21.31M

2024Q3

365

76.69M

18.66%

-50.88M

2024Q2

389

87.45M

21.29%

-59.57M

2024Q1

405

98.68M

24.03%

-57.40M

2023Q4

423

103.82M

25.42%

-56.37M

2023Q3

447

95.61M

23.44%

-78.96M

2023Q2

464

107.90M

26.46%

-89.05M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Sarissa Capital Management, L.P.

1.24M

6.01%

-4.00

-0.00%

Jun 30, 2025

Kynam Capital Management LP

576.11K

2.79%

-44.62K

-7.19%

Jun 30, 2025

Acadian Asset Management LLC

241.05K

1.17%

+51.47K

+27.15%

Jun 30, 2025

Eversept Partners, LP

167.28K

0.81%

-2.68K

-1.58%

Jun 30, 2025

Morgan Stanley & Co. LLC

147.27K

0.71%

+31.23K

+26.91%

Jun 30, 2025

SCP Investment, LP

125.00K

0.6%

--

Jun 30, 2025

Longitude (Cayman) Ltd

81.00K

0.39%

-37.50K

-31.65%

Dec 31, 2024

Berg (Aaron D.)

80.71K

0.39%

+36.64K

+83.12%

Jun 26, 2025

WaterFront Wealth, Inc.

94.73K

0.46%

-31.00K

-24.66%

Jun 30, 2025

Two Sigma Investments, LP

76.39K

0.37%

-86.45K

-53.09%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

Invesco Nasdaq Biotechnology ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.03%

SPDR S&P International Small Cap ETF

0.02%

Global X Aging Population ETF

0%

ActivePassive International Equity ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

SPDR Portfolio Developed World ex-US ETF

0%

Invesco Nasdaq Biotechnology ETF

Proporção0.03%

ProShares Ultra Nasdaq Biotechnology

Proporção0.03%

SPDR S&P International Small Cap ETF

Proporção0.02%

Global X Aging Population ETF

Proporção0%

ActivePassive International Equity ETF

Proporção0%

Invesco NASDAQ Future Gen 200 ETF

Proporção0%

SPDR Portfolio Developed World ex-US ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Mar 12, 2025

Merger

20→1

Data

Tipo

Proporção

Mar 12, 2025

Merger

20→1